Prospective observation study for combination therapy of Docetaxel and Ramucirumab after immunochemotherapy in advanced non-small cell lung cancer patients
Latest Information Update: 13 Jul 2021
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Jul 2021 New trial record